Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.87 USD
0.00 (0.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PRLD 3.87 0.00(0.00%)
Will PRLD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRLD
New Strong Buy Stocks for January 25th
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
Other News for PRLD
Prelude Therapeutics Announces CFO Transition and Interim Appointment
Prelude Therapeutics: A Buy Rating on the Horizon with Promising Preclinical Data and Upcoming Clinical Trials
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Prelude Therapeutics initiated with bullish view at JMP Securities, here's why
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)